[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pathological-conditions-anatomical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pathological-conditions-anatomical":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100494824","phase-3-a-study-of-baricitinib-ly3009104-in-children-from-6-years-to-less-than-18-years-of-age-with-alopecia-areata-100494824",false,"NCT05723198","A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata","A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata","BRAVE-AA-PEDS","Inclusion Criteria:\n\n* Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).\n* Have severe areata alopecia (AA) for at least 1 year\n* Diagnosis for at least 1 year\n* Current AA episode of at least 6 months' duration\n* SALT score ≥50% at screening and baseline\n* History of trial and failure with at least 1 available treatment (topical or other) for AA\n* History of psychological counseling related to AA\n* Current episode of severe AA of less than 8 years.\n\n  * Note: Participants who have severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.\n\nExclusion Criteria:\n\n* Primarily \"diffuse\" type of AA (characterized by diffuse hair shedding).\n* Are currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.\n* Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden\n* Have uncontrolled arterial hypertension\n* Have had major surgery within 8 weeks prior to screening or will require major surgery during the study\n* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.\n* Have a positive test for hepatitis B virus (HBV) infection\n* Have hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid \\[RNA\\]).\n* Have evidence of human immunodeficiency virus (HIV) infection and\u002For positive HIV antibodies.","ALL","6 Years","17 Years",{"count":21,"type":22},595,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension (LTE) Period, and a 4-week Post-treatment Follow-up period. Some individuals may be eligible to receive treatment after completing the LTE, for a maximum of 180 weeks.",[28,29,30,31,32,33],"Areata Alopecia","Alopecia","Hypotrichosis","Hair Diseases","Skin Diseases","Pathological Conditions, Anatomical","RECRUITING","2026-05-18",{"date":37,"type":38},"2026-05-20","ACTUAL",{"date":40,"type":38},"2023-02-27",{"date":42,"type":22},"2033-09",{"name":44,"class":45},"Eli Lilly and Company","INDUSTRY",127,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100605719","prospective-registry-for-long-term-outcomes-following-feto-in-severe-left-and-right-cdh-100605719","NCT07166172","Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH","North American Fetal Therapy Network Prospective Registry for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia","Inclusion Criteria:\n\n* Pregnant women age 18 years and older\n* Singleton pregnancy\n* Normal Karyotype, chromosomal microanalysis (CMA) with non-pathologic variants, whole exome sequencing (WES) or whole genome sequencing (WGS). Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \\> 26 weeks gestation.\n* Gestational age at enrollment is prior to 29 weeks + 6 days gestation.\n* Intrathoracic liver herniation:\n\n  * Isolated left CDH with o\u002Fe LHR \\\u003C 30% at enrollment (18wks + 0 days to 29wks + 5 days gestation).\n  * Isolated right CDH with o\u002Fe LHR ≤ 45% at enrollment (18wks + 0 days to 29wks + 5 days gestation).\n* Cervical length by transvaginal ultrasound ≥ 20 mm within 24 hours prior to FETO procedure.\n* Patient meets psychosocial criteria.\n* Informed consent understood.\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years of age\n* Multi-fetal pregnancy\n* History of natural rubber latex allergy\n* Preterm labor, cervix shortened (\\\u003C20 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa.\n* Psychosocial ineligibility, precluding consent:\n\n  1. Inability to reside within 30 minutes of Johns Hopkins Hospital Center for Fetal Therapy.\n  2. The patient does not have a support person (e.g., spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Johns Hopkins Hospital Center for Fetal Therapy.\n* Bilateral CDH, isolated left sided CDH with O\u002FE LHR ≥ 30% (18wks + 0 days to 29wks + 5 days gestation), isolated right sided CDH with O\u002FE LHR \\> 45% (18wks + 0 days to 29wks + 5 days gestation), as determined by ultrasound.\n* No liver herniation into thoracic cavity.\n* Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. Exclude chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., CDH and congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns).\n* Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy.\n* History of incompetent cervix with or without cerclage.\n* Placental abnormalities (previa, abruption, accreta) known at time of enrollment\n* Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.\n* Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment.\n* Uterine anomalies such as large or multiple fibroids or Mullerian duct abnormality.\n* There is no safe or technically feasible fetoscopic approach to balloon placement.\n* Participation in another intervention study that influences maternal and fetal morbidity and mortality. or participation in this trial in a previous pregnancy.","FEMALE","18 Years",{"count":57,"type":22},80,[59],"NA","This registry study aims to confirm that FETO increases neonatal survival to discharge and reduces long-term morbidity in fetuses with isolated left CDH and o\u002Fe LHR \\\u003C 30%, or isolated right CDH and o\u002Fe LHR ≤ 45%, compared to those receiving standard care. This prospective registry plans to enroll 80 pregnant women (40 treatment\u002F40 control) with fetuses diagnosed with isolated CDH, and the children will be followed for up to 24 months.",[62,63,64,65,66,67,33,68],"Congenital Diaphragmatic Hernia","Congenital Abnormalities","Neonatal Diseases and Abnormalities","Hernia, DIaphragmatic, Congenital","Internal Hernia","Hernia","Pathological Conditions, Signs and Symptoms",[70],"Fetoscopic Endoluminal Tracheal Occlusion","2026-04-20",{"date":73,"type":38},"2026-04-23",{"date":75,"type":38},"2025-06-23",{"date":77,"type":22},"2031-12-01",{"name":79,"class":80},"Johns Hopkins University","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":81},"100606371","phase-2-sglt2-inhibitors-in-geographic-atrophy-100606371","NCT07174687","SGLT2 Inhibitors in Geographic Atrophy","Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol\n2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n3. Participant is male or, if female, participant is surgically sterilized or amenorrheic for at least one year\n4. ≥50 years old\n5. Evidence of dry advanced AMD with the presence of non-foveal Geographic Atrophy (GA)\n\n   1. The geographic atrophy must not involve the center point of the fovea.\n   2. Total area of geographic atrophy must be between 2.5 mm2 and 17.5 mm2 (1 - 4 disc areas, respectively).\n   3. If the geographic atrophy consists of multiple lesions, at least one lesion must have an area of ≥1.25 mm² (equivalent to 0.5 disc areas).\n6. BCVA between 20\u002F25 and 20\u002F320\n7. Must be treatment-naïve for AMD, except for oral supplements\n\nExclusion Criteria:\n\n1. Prior investigational drug use within 60 days\n2. Use of other SGLT2 inhibitors\n3. History of symptomatic hypotension or symptomatic hypotension (symptoms of hypotension + SBP \\\u003C 90mmHg) at baseline\n4. Type I and Type II Diabetes Mellitus\n5. End stage renal disease or estimated glomerular filtration rate less than 25 mL\u002Fmin\u002F1.73 m2 per MDRD calculation\n6. History of heart failure\n7. History of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA\n8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures\n9. Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins or mineral\n10. Any intraocular surgery or thermal laser within 3 months of date of randomization\n11. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks\n12. Any prior thermal laser in the macular region, regardless of indication (self-report)\n13. Any evidence of choroidal neovascularization in study eye\n14. Enrollment in another interventional trial during the trial period","50 Years",{"count":91,"type":22},70,[93],"PHASE2","AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.",[96,97,98,99,33],"Retinal Degeneration","Retinal Diseases","Eye Diseases","Geographic Atrophy",[101,102,103,104,105],"Geographic Atrophy (GA)","Age-related Macular Degeneration","AMD","SGLT2","Dapagliflozin","2025-12-16",{"date":108,"type":38},"2025-12-18",{"date":110,"type":38},"2025-12-02",{"date":112,"type":22},"2028-06",{"name":114,"class":80},"Washington University School of Medicine"]